Weight-loss drug semaglutide shows promising results in treating obesity in children and teens.
TL;DR Summary
Almost half of the children who received a weekly dose of 2.4 milligrams of semaglutide for more than a year lost enough weight to no longer be considered clinically obese, according to a study presented at the European Congress on Obesity. The drug, marketed under the name Ozempic when prescribed for diabetes and Wegovy when prescribed for weight loss, is changing the face of obesity treatment. Semaglutide has been approved by the FDA for the treatment of obesity in 2021 and has an overall excellent safety profile and is generally well tolerated. However, it should only be used under clinical advice.
- Almost half of children on the weight-loss drug semaglutide are no longer clinically obese, landmark study finds Yahoo! Voices
- Half of children given ‘skinny jab’ no longer clinically obese, study finds The Guardian
- Obese teens must be put on weight loss jabs for life, experts say... The US Sun
- Quarter of Wegovy-Treated Teens With Obesity Return to Normal Weight Medpage Today
- Teenagers with obesity should be offered weight loss drug, say experts The Independent
- View Full Coverage on Google News
Reading Insights
Total Reads
0
Unique Readers
21
Time Saved
3 min
vs 4 min read
Condensed
86%
698 → 101 words
Want the full story? Read the original article
Read on Yahoo! Voices